Xpert® vanA
The first rapid & accurate test to assist with VRE surveillance
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
product image
10 Tests
GXVANA-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Collection devices
product image
Collection Device
900-0370
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support

The Need

According to the Centers for Disease Control and Prevention (CDC), about 30% of all healthcare-associated enterococcal infections are caused by Vancomycin-Resistant Enterococci (VRE).1 However, VRE can be even more prevalent in high risk groups, such as immunocompromised and ICU patients.
The human and financial impact of VRE is high2:
  • Attributable mortality: 10%
  • Extended length of stay: 6.2 days
  • Incremental cost: $12,800
* With EAT (Early Assay Termination), for Positive Results
(1)CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019.
(2)Carmeli Y, et al. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med. 2002 Oct 28;162(19):2223-8.

The Solution

The CDC and SHEA have both published guidelines on how to reduce or eliminate healthcare associated infections.3,4 As a part of a quality infection control program, Cepheid's Xpert vanA provides:
  • Rapid and accurate detection of the vanA gene most closely associated with VRE colonization
  • Superior NPV required in a surveillance test
  • Easy-to-use test with minimal hands-on time
(3)Siegel JD, et al. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control. 2007 Dec;35(10 Suppl 2):S165-93.
(4)Muto CA, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol. 2003 May;24(5):362-86.